MedTrace Logo

Apomorphine Effects on Pain in Parkinson's Disease

NCT04879134 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-05-18

No results posted yet for this study

Summary

To study the effects of acute apomorphine vs. placebo administration on different Parkinson's disease pain types.

Conditions

  • Parkinson Disease

Interventions

DRUG

Apomorphine Injectable Solution

Patients will receive the treatment while they are in an OFF period, without the effect of any antiparkinsonian medication. For this study, the initial dose of apomorphine or placebo will be 2 mg. We selected an initial standardized dose based on the pharmacological characteristics of apomorphine. Assessments will be completed 30 and 60 minutes after the initial dose. At 60 minutes from the first dose, a 3 mg dose will be administered, and again, assessments will be completed after 30 and 60 minutes. The total given dosage will be 5 mg. Blood pressure and pulse will be checked every 20 minutes after injections. Other Names: Movapo

DRUG

Placebo

0.9% saline placebo injection Other Names: • Saline

Sponsors & Collaborators

  • Paladin Labs Inc.

    collaborator OTHER

  • University of Calgary

    lead OTHER

Principal Investigators

  • Veronica Bruno, MD, MPH · University of Calgary

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-28
Primary Completion
2023-02-28
Completion
2023-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04879134 on ClinicalTrials.gov